PRMT5 and lung carcinoma: PRMT5 coordinates invasive phenotypes by methylating H3R2me1 for transcriptional activation and H4R3me2s for transcriptional repression, leading to FGFR3 pathway activation (Jing et al, 2018) and TGFβ‐induced EMT (Chen et al, 2017) in lung cancer cells.